Recruiting

Testing a new cholesterol-lowering injection for heart attack patients

Plain-English translation of NCT07102628 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a medication called , which is given as an injection under the skin to lower cholesterol levels. The trial focuses on people who have recently had a heart attack and are still in the hospital. Researchers want to see if starting this medication right away—while you're in the hospital—can help prevent future heart problems and is safe to use at this critical time.

Even after a heart attack, many patients still have cholesterol levels that are higher than ideal, despite taking standard cholesterol medications. This trial is testing whether this new treatment, which works in a different way than traditional pills, can lower cholesterol more effectively when given early, right after a heart attack occurs.

Do you qualify?

You likely qualify if…

you have been hospitalized for a recent heart attack (either a STEMI or NSTEMI)
you are 18 years of age or older
your cholesterol level (LDL-C) is at least 70 mg/dL at screening, even if you've been taking cholesterol medications
you can be screened and enrolled in the study within 7 days of hospital admission and before discharge
you are able to understand the study requirements and agree to follow all study procedures

You likely don't qualify if…

you are in unstable condition during hospitalization, such as having dangerously low blood pressure, dangerous heart rhythm problems, cardiogenic shock, or severe heart failure
you need emergency heart bypass surgery (CABG) as part of your heart attack treatment
you have active liver disease or severe liver problems
you had a heart procedure that was not successful or was not completed

What participation looks like

You would be screened within the first week of your hospital stay, then randomly assigned (like a coin flip) to receive either the new injection or a placebo (fake injection) on top of your regular heart medications. You'll receive your first dose while still in the hospital. The study lasts about 5 months, during which you'll have scheduled visits and phone calls to check on your health and make sure the treatment is working safely. You'll have blood tests to measure your cholesterol levels during the study.

AI-generated summary from trial data · Aug 18, 2026 · Not medical advice

Trial locations(69 sites)

Argentina

Novartis Investigative Site, Capital Federal, Buenos Aires

Australia

Novartis Investigative Site, Garran, Australian Capital Territory

Novartis Investigative Site, Clayton, Victoria

Canada

Novartis Investigative Site, Edmonton, Alberta

Novartis Investigative Site, Hamilton, Ontario